In 2023, Nguyen et al. reported a case of a 61-year-old man with metastatic HS who was treated with pembrolizumab after noting PD-L1 expression in 90% of the tumor cells and had a progression-free survival (PFS) exceeding 30 months [102]. This evidence concerns the gene CD274 and histiocytic sarcoma.